Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer

Kushchayeva, Yevgeniya; Duh, Quan‐Yang; Kebebew, Electron; D'Avanzo, A; Clark, Orlo H.

doi:10.1016/j.amjsurg.2007.06.001

Cited by 83 publications

(61 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Baloch and LiVolsi (34) recently reported that intraoperative consultation is not helpful in the diagnosis of FTC and HTC because this depends on the demonstration of capsular and vascular invasion, which is often not identified on frozen section (35). Several authors recommend total thyroidectomy for HTCs due to the aggressive behavior of this cancer (21,(36)(37)(38)(39)(40)(41)(42), while Wiseman and colleagues (43) suggest that hemithyroidectomy is the optimal initial surgical approach for FN.…”

Section: Discussionmentioning

confidence: 94%

Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate Hürthle Cell Neoplasm

Sorrenti

Trimboli

Catania

et al. 2009

Thyroid

View full text Add to dashboard Cite

There is little difference in the rate of malignancy between thyroid nodules with a cytological reading of FN indeterminate for malignancy and HN indeterminate for malignancy but there is a difference in the types of thyroid cancers in these groups. Hürthle cell thyroid cancer and the oncocytic variant of PTC is more common in nodules with an HN indeterminate for malignancy cytology reading than in nodules with a FN indeterminate for malignancy cytology reading. Since Hürthle cell thyroid cancer and the oncocytic variant of PTC are more aggressive than other thyroid cancers, it is likely that patients with an HN indeterminate for malignancy cytology will, as a group, have more aggressive thyroid cancers than those with an FN indeterminate for malignancy cytology.

show abstract

Section: Discussionmentioning

confidence: 94%

Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate Hürthle Cell Neoplasm

Sorrenti

Trimboli

Catania

et al. 2009

Thyroid

View full text Add to dashboard Cite

show abstract

“…Compared with papillary and follicular thyroid carcinomas, HCC is characterized by higher rates of recurrence, metastasis and cancer-related mortality (5). A study reported that undifferentiated thyroid carcinomas has 100% mortality, and a median survival after diagnosis is 5.5 months, and Hurthle cell cancer has 75% mortality with a mean survival of 33 months (2).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Hurthle Cell Thyroid Carcinoma with Lung and Liver Metastasis Using Docetaxel and Cisplatin

Zhang¹,

Zeng²,

Liang³

et al. 2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

A 36-year-old man was found to have Hurthle cell carcinoma, as diagnosed with surgical pathology after a lobectomy of the thyroid. A post-operative magnetic resonance imaging scan revealed a small mass in the lower pole of the right thyroid and a computed tomography scan showed bilateral nodules in the lungs and the neck, and multi-focal disease in the liver. He was treated with a docetaxel and cisplatin chemotherapy regimen. After six cycles of the docetaxel and cisplatin regimen, we could hardly find the lesions in the lungs and the liver, and the patient presented a complete tumor response lasting 17 months and has not shown any tumor recurrence till now. The docetaxel and cisplatin regimen may be an effective chemotherapy regimen for multi-metastases of Hurthle cell cancer.

show abstract

“…In addition, pure Hurthle cell tumors do not accumulate iodine but tend to be locally aggressive and can again be very difficult to treat [9].…”

Section: Suprasternal Notch Markermentioning

confidence: 99%

Nuclear medicine in the management of thyroid disease

Buscombe¹,

Hirji²,

Witney-Smith³

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Thyroid disease management has changed little over the last 60 years and recent work suggests that the older approach remains the most effective. Treatment of benign hyperthyroidism has shown that functional imaging is essentially linked to therapy and uptake of iodine-131 ((131)I) cannot be assumed but should be tested by pre-imaging with radio-isotopes as 10% of patients may not be suitable for (131)I therapy and 1% may have a co-existent cancer. Differentiated thyroid cancer remains unique in that it is almost alone among common solid tumors in that it is routinely cured even if cannot all be removed by surgery. This is achieved in the majority of patients by a treatment introduced in the 1940s and does not involve the use of chemotherapy drugs but a simple and cheap isotope preparation; (131)I. However, in some differentiated thyroid cancers there is no accumulation of (131)I and we know this is due to the loss, or downregulation of the sodium iodide symporter gene. This has led to the development of several strategies to overcome this loss/downregulation, for example with the use of lithium or retinoids or gene treatment. However, all these approaches have yet to be proved in a randomized controlled trial. Advances in imaging especially using (18)F-fluorodeoxy-glucose PET has enabled patients with thyroid cancer to be more accurately imaged, resulting in a greater chance of cure through surgery and external-beam radiotherapy, especially if uptake of (131)I is poor. Another approach has been the idea of using radiolabeled somatostatin analogs, which are able to demonstrate uptake in the tumor and, more recently, beta-emitting isotopes have been used for therapy when other options have failed. Therefore, whilst the treatment of differentiated thyroid cancer is, to some degree, 60 years old, new methods have been proposed and are now being tested in this disease.

show abstract

Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer

Cited by 83 publications

References 33 publications

Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate Hürthle Cell Neoplasm

Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate Hürthle Cell Neoplasm

Successful Treatment of Hurthle Cell Thyroid Carcinoma with Lung and Liver Metastasis Using Docetaxel and Cisplatin

Nuclear medicine in the management of thyroid disease

Contact Info

Product

Resources

About